» Articles » PMID: 2171331

Identification of Point Mutations in the Alpha-galactosidase A Gene in Classical and Atypical Hemizygotes with Fabry Disease

Overview
Journal Am J Hum Genet
Publisher Cell Press
Specialty Genetics
Date 1990 Nov 1
PMID 2171331
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Efforts were directed to identify the specific mutations in the alpha-galactosidase A (alpha-Gal A) gene which cause Fabry disease in families of Japanese origin. By polymerase-chain-reaction-amplification of DNA from reverse-transcribed mRNA and genomic DNA, different point mutations were found in two unrelated Fabry hemizygotes. A hemizygote with classic disease manifestations and no detectable alpha-Gal A activity had a G-to-A transition in exon 1 (codon 44) which substituted a termination codon (TAG) for a tryptophan codon (TGG) and created an NheI restriction site. This point mutation would predict a truncated alpha-Gal A polypeptide, consistent with the observed absence of enzymatic activity and a classic Fabry phenotype. In an unrelated Japanese hemizygote who had an atypical clinical course characterized by late-onset cardiac involvement and significant residual alpha-Gal activity, a G-to-A transition in exon 6 (codon 301) resulted in the replacement of a glutamine for an arginine residue. This amino acid substitution apparently altered the properties of the enzyme such that sufficient enzymatic activity was retained to markedly alter the disease course. Identification of these mutations permitted accurate molecular heterozygote diagnosis in these families.

Citing Articles

Sex Differences in Anderson-Fabry Cardiomyopathy: Clinical, Genetic, and Imaging Analysis in Women.

Faro D, Losi V, Rodolico M, Torrisi E, Colomba P, Duro G Genes (Basel). 2023; 14(9).

PMID: 37761944 PMC: 10531426. DOI: 10.3390/genes14091804.


Acceleration of the Deamination of Cytosine through Photo-Crosslinking.

Sethi S, Takashima Y, Nakamura S, Wan L, Honda N, Fujimoto K Curr Issues Mol Biol. 2023; 45(6):4687-4700.

PMID: 37367047 PMC: 10297672. DOI: 10.3390/cimb45060298.


The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.

Savostyanov K, Pushkov A, Zhanin I, Mazanova N, Trufanov S, Pakhomov A Orphanet J Rare Dis. 2022; 17(1):199.

PMID: 35578305 PMC: 9109305. DOI: 10.1186/s13023-022-02319-4.


Retinal vessel tortuosity as a prognostic marker for disease severity in Fabry disease.

Atiskova Y, Wildner J, Spitzer M, Aries C, Muschol N, Dulz S Orphanet J Rare Dis. 2021; 16(1):485.

PMID: 34801073 PMC: 8605526. DOI: 10.1186/s13023-021-02080-0.


Plasma Globotriaosylsphingosine and α-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort.

Maruyama H, Taguchi A, Mikame M, Izawa A, Morito N, Izaki K Curr Issues Mol Biol. 2021; 43(1):389-404.

PMID: 34205365 PMC: 8928976. DOI: 10.3390/cimb43010032.


References
1.
Clarke J, KNAACK J, Crawhall J, Wolfe L . Ceramide trihexosidosis (fabry's disease) without skin lesions. N Engl J Med. 1971; 284(5):233-5. DOI: 10.1056/NEJM197102042840503. View

2.
Sweeley C, KLIONSKY B . FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID. J Biol Chem. 1963; 238:3148-50. View

3.
Romeo G, DUrso M, Pisacane A, Blum E, De Falco A, Ruffilli A . Residual activity of alpha-galactosidase A in Fabry's disease. Biochem Genet. 1975; 13(9-10):615-28. DOI: 10.1007/BF00484919. View

4.
SANGER F, Nicklen S, Coulson A . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74(12):5463-7. PMC: 431765. DOI: 10.1073/pnas.74.12.5463. View

5.
Bach G, Rosenmann E, Karni A, Cohen T . Pseudodeficiency of alpha-galactosidase A. Clin Genet. 1982; 21(1):59-64. View